Skip to main content

Advertisement

SpringerLink
Log in

High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Development of malignancies in BRCA1 germ-line mutation carriers usually involves somatic inactivation of the remaining BRCA1 allele. This feature leads to a tumor-specific deficiency of double-strand DNA break repair and underlies pronounced sensitivity of BRCA1-driven cancers to cisplatin. BRCA1-specific activity of cisplatin has been repeatedly demonstrated in cell culture and animal experiments; however, corresponding clinical evidence remains limited. We applied neoadjuvant monotherapy by cisplatin (75–100 mg/m2, 4–6 cycles) to six breast cancer patients carrying BRCA1 5382insC mutation. Pronounced reduction in tumor size was observed in all treated women. Three patients (T2N0M0, T4N2M0 and T4N2M0) showed pathologic complete response, two women (T4N0M0 and T2N1M0) had partial pathologic response, and one woman (T3N2M0) declined surgery. This study and available literature data suggest that cisplatin is a preferable option for systemic treatment of BRCA1-related hereditary breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 2011;9(1):5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115(2):359–63.

    Article  CAS  PubMed  Google Scholar 

  3. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375–9.

    Article  CAS  PubMed  Google Scholar 

  4. Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, Lubinski J, Narod SA. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401–5.

    Article  CAS  PubMed  Google Scholar 

  5. Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z. Pathological complete response in younger and older breast cancer patients. Arch Med Sci. 2012;8(2):310–5.

    PubMed Central  PubMed  Google Scholar 

  6. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. Clin Oncol. 2011;29(28):3739–46.

    Article  CAS  Google Scholar 

  8. Pfeifer W, Sokolenko AP, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, Zaitseva OA, Yatsuk OS, Matsko DE, Semiglazova TY, Togo AV, Imyanitov EN. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res Treat. 2014;148(3):675–83.

    Article  CAS  PubMed  Google Scholar 

  9. Sokolenko AP, Voskresenskiy DA, Iyevleva AG, Bit-Sava EM, Gutkina NI, Anisimenko MS, Yu Sherina N, Mitiushkina NV, Ulibina YM, Yatsuk OS, Zaitseva OA, Suspitsin EN, Togo AV, Pospelov VA, Kovalenko SP, Semiglazov VF, Imyanitov EN. Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hered Cancer Clin Pract. 2009;7(1):2.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the by the Russian Scientific Fund (Grant Number 14-25-00111).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. City Cancer Center, St.-Petersburg, 197758, Russia

    Vladimir M. Moiseyenko, Fedor V. Moiseyenko, Vyacheslav A. Chubenko & Nuriniso Kh. Abduloeva

  2. City Cancer Hospital, St.-Petersburg, 197022, Russia

    Georgiy D. Dolmatov

  3. N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia

    Fedor V. Moiseyenko, Alexandr O. Ivantsov, Nikita M. Volkov, Anna P. Sokolenko & Evgeny N. Imyanitov

  4. I.I. Mechnikov North-Western Medical University, St.-Petersburg, 191015, Russia

    Fedor V. Moiseyenko & Evgeny N. Imyanitov

  5. St.-Petersburg Academic University, St.-Petersburg, 194021, Russia

    Alexey A. Bogdanov

  6. St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia

    Anna P. Sokolenko & Evgeny N. Imyanitov

  7. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, St.-Petersburg, 197758, Russia

    Evgeny N. Imyanitov

Authors
  1. Vladimir M. Moiseyenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georgiy D. Dolmatov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fedor V. Moiseyenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandr O. Ivantsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nikita M. Volkov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vyacheslav A. Chubenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nuriniso Kh. Abduloeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexey A. Bogdanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Anna P. Sokolenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Evgeny N. Imyanitov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evgeny N. Imyanitov.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moiseyenko, V.M., Dolmatov, G.D., Moiseyenko, F.V. et al. High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation. Med Oncol 32, 89 (2015). https://doi.org/10.1007/s12032-015-0514-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0514-1

Keywords

Search

Navigation